In the Claims

1. (Previously presented) A peptide of the formula

X-D-Phe-Gln-R1-R2-Val-R3-His-R4-NH_2

wherein X is acetyl or straight, branched or cyclic alkanoyl group from 3-16 carbon atoms, or X is deleted

R1 is Trp or D-Trp,

R2 is Ala, Aib or Deg,

R3 is Gly, Aib, Deg, Dpg or Ac5c,

R4 is Leu or Ile

or a hydrolyzable carboxy protecting group; wherein at least one of R2 or R3 is an α,α- dialkylated amino acid; or a pharmaceutically acceptable salt of the peptide.wherein Aib is α-aminoisobutyric acid, Deg is α,α-diethyl glycine, Dpg is α,α-di-n-propyl glycine and Ac5c is 1-amino-cyclo pentane carboxylic acid.

2. (Previously presented) The peptide of claim 1, wherein X is deleted, R1 is Trp, R2 is Ala, R3 is Aib and R4 is Leu, and said peptide has the formula:

D-Phe-Gln-Trp-Ala-Val-Aib-His-Leu-NH_2 (SEQ ID NO: 3)

or a pharmaceutically acceptable salt thereof.

3. (Previously presented) The peptide of claim 1, wherein X is deleted, R1 is Trp, R2 is Aib, R3 is Gly and R4 is Leu, and said peptide has the formula:

D-Phe-Gln-Trp-Aib-Val-Gly-His-Leu-NH_2 (SEQ ID NO: 4)

or a pharmaceutically acceptable salt thereof.

4. (Previously presented)The peptide of claim 1, wherein X is deleted, R1 is D-Trp, R2 is Ala, R3 is Aib and R4 is Leu, and said peptide has the formula:

D-Phe-Gln-D-Trp-Ala-Val-Aib-His-Leu-NH_2 (SEQ ID NO:5)

or a pharmaceutically acceptable salt thereof.

5. (Previously presented) The peptide of claim 1, wherein X is deleted, R1 is Trp, R2 is Aib, R3 is Gly and R4 is Ile, and said peptide has the formula:

D-Phe-Gln-Trp-Aib-Val-Gly-His-Ile-NH_2 (SEQ ID NO: 6)

or a pharmaceutically acceptable salt thereof.

6. (Previously presented) The peptide of claim 1, wherein X is deleted, R1 is Trp, R2 is Ala, R3 is Aib and R4 is Ile, and said peptide has the formula:

D-Phe-Gln-Trp-Ala-Val-Aib-His-Ile-NH_2 (SEQ ID NO:7)

or a pharmaceutically acceptable salt thereof.

7. (Previously presented) The peptide of claim 1, wherein X is deleted, R1 is D-Trp, R2 is Ala, R3 is Dpg and R4 is Leu, and said peptide has the formula:

D-Phe-Gln-D-Trp-Ala-Val-Dpg-His-Leu-NH_2 (SEQ ID NO:8)

or a pharmaceutically acceptable salt thereof.

8. (Previously presented) The peptide of claim 1, wherein X is deleted, R1 is Trp, R2 is Deg, R3 is Gly and R4 is Leu, and said peptide has the formula:

D-Phe-Gln-Trp-Deg-Val-Gly-His-Leu-NH_2 (SEQ ID NO:9)

or a pharmaceutically acceptable salt thereof.

9. (Previously presented) The peptide of claim 1, wherein X deleted, R1 is Trp, R2 is Ala, R3 is Ac5c and R4 is Leu, and said peptide has the formula:

D-Phe-Gln-Trp-Ala-Val-Ac5c-His-Leu-NH_2 (SEQ ID NO: 10)

or a pharmaceutically acceptable salt thereof.

10. (Currently amended) The peptide of claim 1, wherein X is butanoyl, R1 is Trp, R2 is Ala, R3 is [[~~Alb~~]] Aib and R4 is Leu, and said peptide has the formula:

Butanoyl-D-Phe-Gln-Trp-Ala-Val-Aib-His-Leu-NH_2 (SEQ ID NO: 11)

or a pharmaceutically acceptable salt thereof.

11. (Currently amended) The peptide of claim 1, wherein X is octanoyl, R1 is Trp, R2 is Ala, R3 is [[Alb]] Aib and R4 is Leu and said peptide has the formula:

Octanoyl-D-Phe-Gln-Trp-Ala-Val-Aib-His-Leu-NH_2 (SEQ ID NO: 12)

or a pharmaceutically acceptable salt thereof.

12. (Currently amended) A composition comprising an effective amount of [[a]] the peptide according to claim 1, and a pharmaceutically acceptable carrier.

13. (Currently amended) A method of treatment of cancer in a mammal which comprises administering an ~~effective~~ amount of [[a]] the peptide according to claim 1 to the mammal in need thereof effective to treat the cancer, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

Claims 14-20 (cancelled)

21. (Previously presented) A composition comprising a peptide according to claim 2, and a pharmaceutically acceptable carrier.

22. (Previously presented) A composition comprising a peptide according to claim 3, and a pharmaceutically acceptable carrier.

23. (Previously presented) A composition comprising a peptide according to claim 4, and a pharmaceutically acceptable carrier.

24. (Previously presented) A composition comprising a peptide according to claim 5, and a pharmaceutically acceptable carrier.

25. (Previously presented) A composition comprising a peptide according to claim 6, and a pharmaceutically acceptable carrier.

26. (Previously presented) A composition comprising a peptide according to claim 7, and a pharmaceutically acceptable carrier.

27. (Previously presented) A composition comprising a peptide according to claim 8, and a pharmaceutically acceptable carrier.

28. (Previously presented) A composition comprising a peptide according to claim 9, and a pharmaceutically acceptable carrier.

29. (Previously presented) A composition comprising a peptide according to claim 10, and a pharmaceutically acceptable carrier.

30. (Previously presented) A composition comprising a peptide according to claim 11, and a pharmaceutically acceptable carrier.

31. (Previously presented) A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim

2 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

32. (Previously presented) A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 3 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

33. (Previously presented) A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 4 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

34. (Previously presented) A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 5 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

35. (Previously presented) A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 6 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

36. (Previously presented) A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 7 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or

glioblastoma.

37. (Previously presented) A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 8 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

38. (Previously presented) A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 9 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

39. (Previously presented) A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 10 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

40. (Previously presented) A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 11 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

Claims 41- 50 (cancelled)